Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, use different ways
to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as
trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances
to them without harming normal cells. It is not yet known whether docetaxel and carboplatin
are more effective with or without trastuzumab in treating breast cancer.
PURPOSE: This randomized phase II trial is studying how well giving docetaxel together with
carboplatin and trastuzumab before surgery works compared to docetaxel and carboplatin alone
before surgery in treating women with locally advanced breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Aventis Pharmaceuticals Genentech, Inc. National Cancer Institute (NCI)